vTv Therapeutics Inc.
Income Statement
| Line Item | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 |
|---|---|---|---|---|---|
| Revenue | $291.0K | $634.0K | $519.0K | $1.5M | $976.0K |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Gross Margin | — | — | — | — | — |
| Operating Expenses | |||||
| Research & Development | $39.6M | $45.0M | $27.2M | $17.4M | $22.3M |
| SG&A Expense | $11.3M | $9.9M | $9.1M | $11.7M | $11.4M |
| Operating Income | $-50.7M | $-55.0M | $-38.1M | $-28.9M | $-35.8M |
| Operating Margin | -17,416.5% | -8,678.2% | -7,349.1% | -1,865.5% | -3,671.4% |
| Interest Expense | $3.1M | $398.0K | $108.0K | $286.0K | $476.0K |
| Pretax Income | $-53.8M | $-55.4M | $-41.1M | $-36.1M | $-48.2M |
| Income Tax Expense | $800.0K | $0 | $0 | $0 | — |
| Net Income | $-16.1M | $-16.4M | $-27.5M | $-36.1M | $-48.2M |
| Net Margin | -5,547.8% | -2,579.2% | -5,298.3% | -2,330.6% | -4,938.8% |
| EPS (Basic) | — | — | — | — | — |
| EPS (Diluted) | — | — | — | — | — |
| Shares Outstanding (Basic) | — | — | — | — | — |
| Shares Outstanding (Diluted) | — | — | — | — | — |
| Dividends Per Share | — | — | — | — | — |